Compare TKLF & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKLF | RGNT |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | Japan | Israel |
| Employees | N/A | 8 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 6.8M |
| IPO Year | 2020 | N/A |
| Metric | TKLF | RGNT |
|---|---|---|
| Price | $1.98 | $1.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 106.3K | ★ 3.9M |
| Earning Date | 12-19-2025 | 05-05-2026 |
| Dividend Yield | ★ 10.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $1.23 |
| 52 Week High | $4.32 | $8.35 |
| Indicator | TKLF | RGNT |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 47.46 |
| Support Level | N/A | $1.82 |
| Resistance Level | $2.41 | $3.35 |
| Average True Range (ATR) | 0.24 | 0.55 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 14.92 | 13.32 |
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.